Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid. 1990

D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
Department of Chemical Research, A.H. Robins Company, Richmond, Virginia 23261-6609.

A series of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid (amfenac) and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid were synthesized and evaluated for their cyclooxygenase inhibiting properties, antiinflammatory potency, and gastrointestinal irritation liability. One compound, 2-amino-3-(4-chlorobenzoyl)benzeneacetamide, possessed a therapeutic index 1 order of magnitude greater than that of indomethacin.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002351 Carrageenan A water-soluble extractive mixture of sulfated polysaccharides from RED ALGAE. Chief sources are the Irish moss CHONDRUS CRISPUS (Carrageen), and Gigartina stellata. It is used as a stabilizer, for suspending COCOA in chocolate manufacture, and to clarify BEVERAGES. Carrageenin,iota-Carrageenan,kappa-Carrageenan,lambda-Carrageenan,iota Carrageenan,kappa Carrageenan,lambda Carrageenan
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D005260 Female Females
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.

Related Publications

D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
April 2013, Acta crystallographica. Section E, Structure reports online,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
September 1979, Journal of medicinal chemistry,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
February 2002, Molecular cancer therapeutics,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
April 1982, Journal of medicinal chemistry,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
April 2002, British journal of cancer,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
March 2014, Organic & biomolecular chemistry,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
September 2010, Indian journal of pharmaceutical sciences,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
November 2009, Basic & clinical pharmacology & toxicology,
D A Walsh, and H W Moran, and D A Shamblee, and W J Welstead, and J C Nolan, and L F Sancilio, and G Graff
January 1980, Journal of medicinal chemistry,
Copied contents to your clipboard!